MarketCapExport financials
Zimmer Biomet Holdings (ZBH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Zimmer Biomet Holdings Income Statement 2025-2006 | ZBH
Brief overview of profit and loss at Zimmer Biomet Holdings
This overview is based on financial performance over the past five years. Revenue reported by Zimmer Biomet Holdings was 6.1 billion dollars at the beginning of the period and 8.2 billion dollars at the end. The cumulative result was +34.3%, corresponding to roughly 6.1% per year. Sales increased steadily, although without strong acceleration.
Gross profit was $4.3 billion at the start and $5.7 billion at the end of the period (+33.3%). The relationship between revenue and direct costs remained stable. Comparing the endpoints gives gross margins of 70.2% and 69.7%. The gross margin stayed within a similar range.
EBITDA changed from $982 million to $2.2 billion (+123.3%). Operating profitability strengthened faster than the scale of sales. Comparing the endpoints gives EBITDA margins of 16% and 26.6%. The increased EBITDA share is a positive sign.
The final result was −$139 million initially and $705 million in the final year. The trajectory reversed from a loss to positive earnings.
Market value was 30.7 billion dollars at the start and 16.3 billion dollars at the end. Investors remain cautious despite better financial results.
Overall conclusion
Positive developments coexist with areas of weakness. The financial profile benefits from revenue expansion, higher operating efficiency and consistent sales economics. Caution is warranted because of declining capitalization. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Zimmer Biomet Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
16.3 B | 21.8 B | 26.9 B | 25.7 B | 25.7 B | 30.7 B | 31 B | 22.1 B | 25.4 B | 23.1 B | 18.6 B | 17.5 B | 15.8 B | 13 B | 11.4 B | 10.5 B | 9.54 B | 16 B | 20.1 B | - |
Shares |
198 M | 203 M | 209 M | 210 M | 209 M | 207 M | 205 M | 204 M | 202 M | 200 M | 187 M | 169 M | 170 M | 175 M | 188 M | 200 M | 215 M | 227 M | 236 M | - |
Historical Prices |
82.3 | 107 | 129 | 123 | 123 | 148 | 143 | 98.2 | 113 | 96.1 | 94.7 | 104 | 84.4 | 59.7 | 47.4 | 52.6 | 44.4 | 70.3 | 85.5 | 59.3 |
Net Income |
705 M | 904 M | 1.02 B | 231 M | 402 M | -139 M | 1.13 B | -379 M | 1.81 B | 306 M | 147 M | 720 M | 761 M | 755 M | 761 M | 597 M | 717 M | 849 M | 773 M | - |
Revenue |
8.23 B | 7.68 B | 7.39 B | 6.94 B | 6.83 B | 6.13 B | 7.98 B | 7.93 B | 7.82 B | 7.68 B | 6 B | - | 4.62 B | 4.47 B | 4.45 B | - | - | - | - | - |
Cost of Revenue |
2.49 B | 2.19 B | 2.08 B | 2.02 B | 1.96 B | 1.82 B | 1.94 B | 2.27 B | 2.13 B | 2.38 B | - | - | - | - | - | 1.01 B | 991 M | 997 M | 876 M | - |
Gross Profit |
5.74 B | 5.49 B | 5.31 B | 4.92 B | 4.87 B | 1.29 B | 5.73 B | 5.66 B | 5.69 B | 5.3 B | 4.2 B | 889 M | 3.34 B | 3.35 B | 3.33 B | 3.21 B | 3.1 B | 3.12 B | 3.02 B | - |
Operating Income |
1.1 B | 1.29 B | 1.28 B | 696 M | 860 M | 83.1 M | 1.11 B | 33.8 M | 799 M | 821 M | 467 M | 1.04 B | 1.07 B | 1.05 B | 1.02 B | 917 M | 1.02 B | 1.09 B | 1.13 B | - |
Interest Expense |
25.5 M | -31.1 M | -9.3 M | -128 M | 12.2 M | 23.8 M | -4.9 M | -15.6 M | -9.4 M | -66.5 M | -36.9 M | -46.7 M | - | - | - | - | - | - | - | - |
EBITDA |
2.19 B | 2.28 B | 2.23 B | 1.62 B | 1.8 B | 982 M | 1.85 B | 1.74 B | 1.95 B | 1.65 B | 1.27 B | 1.41 B | 1.17 B | 1.21 B | 1.46 B | 1.26 B | 1.36 B | 1.37 B | 1.36 B | - |
Operating Expenses |
4.64 B | 4.2 B | 4.03 B | 4.22 B | 4.01 B | 1.2 B | 4.46 B | 4.51 B | 4.34 B | 4.21 B | 3.27 B | 3.64 B | 2.18 B | 2.14 B | 2.23 B | 2.29 B | 2.09 B | 2.03 B | 1.89 B | - |
General and Administrative Expenses |
3.26 B | 2.93 B | 2.84 B | 2.76 B | 2.84 B | 2.71 B | 3.34 B | 3.38 B | 3.37 B | 3.28 B | 2.66 B | 1.75 B | 1.97 B | 1.91 B | 1.99 B | 1.76 B | 1.73 B | 1.7 B | 1.52 B | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Zimmer Biomet Holdings
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q4 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
190 M | 192 M | 195 M | -300 K | 198 M | 198 M | 199 M | -1.3 M | 202 M | 206 M | 205 M | -300 K | 209 M | 209 M | 209 M | 100 M | 210 M | 210 M | 209 M | 100 M | 209 M | 209 M | 208 M | 200 M | 207 M | 207 M | 206 M | 300 M | 205 M | 205 M | 204 M | 200 M | 204 M | 203 M | 203 M | 200 M | 202 M | 202 M | 201 M | 100 M | 200 M | 199 M | 200 M | 5.3 M | 204 M | 173 M | 170 M | 200 M | 169 M | 168 M | 169 M | 400 K | 170 M | 169 M | 169 M | -700 K | 174 M | 175 M | 177 M | -3 M | 188 M | 192 M | 193 M | -1.2 M | 199 M | 202 M | 203 M | -1.6 M | 214 M | 215 M |
Net Income |
193 M | 200 M | 238 M | 138 M | 231 M | 153 M | 183 M | 240 M | 249 M | 243 M | 173 M | 420 M | 163 M | 210 M | 233 M | -130 M | 194 M | 154 M | 14.4 M | -83.9 M | 146 M | 142 M | 198 M | 334 M | 246 M | -208 M | -509 M | 321 M | 432 M | 132 M | 246 M | -901 M | 162 M | 185 M | 176 M | 1.23 B | 98.8 M | 184 M | 299 M | 69.6 M | 158 M | -31.7 M | 109 M | 127 M | 22.2 M | -174 M | 171 M | 154 M | 173 M | 176 M | 221 M | 236 M | 154 M | 152 M | 218 M | 153 M | 178 M | 214 M | 209 M | 157 M | 191 M | 204 M | 209 M | 34.9 M | 191 M | 166 M | 205 M | 155 M | 150 M | 210 M |
Revenue |
2.06 B | 2.18 B | 2.09 B | 2.24 B | 2 B | 2.08 B | 1.91 B | 2.02 B | 1.82 B | 1.94 B | 1.89 B | 1.94 B | 1.75 B | 1.87 B | 1.83 B | 1.83 B | 1.67 B | 1.78 B | 1.66 B | 1.78 B | 1.69 B | 1.76 B | 1.6 B | 2.09 B | 1.93 B | 1.23 B | 1.78 B | 2.13 B | 1.89 B | 1.99 B | 1.98 B | 2.07 B | 1.84 B | 2.01 B | 2.02 B | 2.07 B | 1.81 B | 1.95 B | 1.97 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.12 B | - | - | - | - | - | - | - |
Cost of Revenue |
594 M | 636 M | 576 M | 792 M | 559 M | 592 M | 550 M | 587 M | 539 M | 554 M | 512 M | 539 M | 519 M | 526 M | 501 M | 520 M | 488 M | 511 M | 500 M | 536 M | 491 M | 496 M | 436 M | 343 M | 569 M | 424 M | 487 M | 582 M | 536 M | 581 M | 553 M | 583 M | 529 M | 584 M | 576 M | 591 M | 501 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 279 M | 274 M | 219 M | 251 M | 268 M | 274 M | 249 M | 237 M |
Gross Profit |
1.47 B | 1.54 B | 1.51 B | 1.45 B | 1.44 B | 1.49 B | 1.36 B | 1.44 B | 1.29 B | 1.39 B | 1.38 B | 1.4 B | 1.24 B | 1.34 B | 1.33 B | 1.3 B | 1.18 B | 1.27 B | 1.16 B | 1.24 B | 1.19 B | 1.27 B | 1.17 B | 1.29 B | 1.21 B | 654 M | 1.15 B | 1.4 B | 1.21 B | 1.26 B | 1.28 B | 1.34 B | 1.16 B | 1.27 B | 1.29 B | 1.33 B | 1.16 B | 1.27 B | 1.31 B | 1.25 B | 1.19 B | 1.16 B | 1.14 B | 1.1 B | 1.09 B | 840 M | 829 M | 889 M | 790 M | 833 M | 827 M | 900 M | 746 M | 846 M | 846 M | 882 M | 770 M | 843 M | 852 M | 864 M | 780 M | 850 M | 837 M | 860 M | 746 M | 807 M | 794 M | 833 M | 726 M | 783 M |
Operating Income |
308 M | 326 M | 373 M | 154 M | 351 M | 300 M | 292 M | 389 M | 280 M | 351 M | 266 M | 354 M | 267 M | 330 M | 327 M | -28.3 M | 245 M | 281 M | 198 M | 134 M | 243 M | 225 M | 259 M | 412 M | 299 M | -172 M | -456 M | 337 M | 246 M | 205 M | 350 M | -790 M | 223 M | 296 M | 305 M | -40.1 M | 211 M | 280 M | 348 M | 178 M | 196 M | 202 M | 246 M | 214 M | 116 M | -132 M | 270 M | 226 M | 255 M | 261 M | 300 M | 348 M | 212 M | 210 M | 298 M | 200 M | 249 M | 302 M | 296 M | 201 M | 267 M | 259 M | 297 M | 123 M | 272 M | 228 M | 294 M | 238 M | 204 M | 296 M |
Interest Expense |
-74.9 M | -72.9 M | -68.8 M | -71.9 M | -75.4 M | -79.3 M | -66.2 M | -61.9 M | -54.3 M | -51.1 M | -50.7 M | -50.3 M | -51.1 M | -51.6 M | -48.2 M | -42.6 M | -42.3 M | -38.8 M | -41.1 M | -48.8 M | -52.6 M | -54.7 M | -52.3 M | -53.2 M | -54 M | -54 M | -50.9 M | -52.4 M | -56.8 M | -59.7 M | -58 M | -68.5 M | -67.5 M | -75.3 M | -78 M | -321 M | -2.3 M | -1.7 M | -500 K | -346 M | -1.1 M | -3.8 M | -3.8 M | 7.7 M | 4.3 M | - | - | -21.3 M | -12.1 M | - | - | - | - | - | - | - | - | - | - | - | -11.7 M | -9.8 M | -11 M | - | -14.2 M | -14.3 M | -14.6 M | - | - | - |
EBITDA |
474 M | 490 M | 535 M | 332 M | 528 M | 461 M | 443 M | 547 M | 428 M | 495 M | 408 M | 499 M | 412 M | 468 M | 461 M | 103 M | 377 M | 414 M | 329 M | 265 M | 375 M | 358 M | 392 M | 479 M | 449 M | -24 M | -308 M | 484 M | 392 M | 352 M | 494 M | -642 M | 371 M | 446 M | 456 M | 111 M | 364 M | 428 M | 500 M | 320 M | 360 M | 335 M | 372 M | 375 M | 239 M | -99.1 M | 290 M | 247 M | 276 M | 283 M | 329 M | 158 M | 304 M | 302 M | 383 M | 24.7 M | 332 M | 395 M | 392 M | 29.4 M | 358 M | 348 M | 383 M | -34.3 M | 355 M | 309 M | 379 M | 238 M | 292 M | 458 M |
Operating Expenses |
1.16 B | 1.22 B | 1.14 B | 1.3 B | 1.09 B | 1.19 B | 1.07 B | 1.05 B | 1.01 B | 1.04 B | 1.11 B | 1.05 B | 968 M | 1.01 B | 1 B | 1.33 B | 936 M | 990 M | 965 M | 1.11 B | 951 M | 1.04 B | 906 M | 874 M | 911 M | 826 M | 1.61 B | 1.06 B | 964 M | 1.06 B | 928 M | 2.13 B | 937 M | 978 M | 986 M | 1.37 B | 948 M | 994 M | 959 M | 1.07 B | 994 M | 1.73 B | 1.66 B | 1.72 B | 1.65 B | 1.3 B | 864 M | 997 M | 851 M | 590 M | 558 M | 1.84 B | 534 M | 636 M | 548 M | 681 M | 520 M | 541 M | 556 M | 663 M | 513 M | 590 M | 539 M | 738 M | 474 M | 579 M | 500 M | 594 M | 522 M | 487 M |
General and Administrative Expenses |
855 M | 899 M | 850 M | 872 M | 811 M | 815 M | 759 M | 747 M | 710 M | 737 M | 736 M | 722 M | 675 M | 726 M | 716 M | 727 M | 655 M | 695 M | 684 M | 805 M | 684 M | 697 M | 657 M | 429 M | 790 M | 665 M | 829 M | 882 M | 826 M | 839 M | 796 M | 999 M | 788 M | 791 M | 802 M | 865 M | 712 M | 752 M | 758 M | 768 M | 728 M | 732 M | 717 M | 724 M | 692 M | 444 M | 424 M | 439 M | 423 M | 436 M | 444 M | 392 M | 438 M | 458 M | 461 M | 460 M | 430 M | 453 M | 463 M | 462 M | 444 M | 470 M | 458 M | 462 M | 412 M | 438 M | 447 M | 460 M | 413 M | 432 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Zimmer Biomet Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
$ 110.59 | 0.07 % | $ 193 B |  USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
$ 174.54 | 0.16 % | $ 12.7 B | USA |
 |
TELA Bio
TELA
|
$ 0.83 | -4.37 % | $ 39 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
$ 104.0 | -0.68 % | $ 60.8 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
$ 51.21 | -1.42 % | $ 1.59 B | USA |
 |
Medtronic PLC
MDT
|
$ 101.59 | -1.17 % | $ 130 B | USA |
 |
MiMedx Group
MDXG
|
$ 3.37 | 1.36 % | $ 498 M | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Myomo
MYO
|
$ 1.32 | -5.71 % | $ 55.2 M | USA |
 |
Insulet Corporation
PODD
|
$ 148.03 | -1.19 % | $ 10.4 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 7.66 | 4.36 % | $ 232 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.3 | -2.51 % | $ 141 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 30.96 | -0.29 % | $ 26.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 3.42 | 7.39 % | $ 55.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 324.18 | -0.48 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.61 | 0.08 % | $ 609 M | USA |
 |
TransMedics Group
TMDX
|
$ 91.02 | -2.95 % | $ 3.09 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Viemed Healthcare
VMD
|
$ 9.04 | 1.01 % | $ 352 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.14 % | $ 925 K | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -0.68 % | $ 39.1 M | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.37 | 59.63 % | $ 24 M |  Israel |
 |
Penumbra
PEN
|
$ 321.48 | -0.11 % | $ 12.5 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 1.49 % | $ 66.1 B | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |